Evaxion Biotech A/S Forecasted to Earn Q3 2024 Earnings of ($0.12) Per Share (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX) – Investment analysts at Zacks Small Cap cut their Q3 2024 EPS estimates for Evaxion Biotech A/S in a research report issued on Wednesday, August 14th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of ($0.12) per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.03) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.47) EPS.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.14). The company had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same period in the prior year, the company earned ($2.10) earnings per share.

Separately, HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a report on Friday, August 16th.

Evaxion Biotech A/S Stock Down 5.0 %

NASDAQ EVAX opened at $3.23 on Monday. The stock has a market capitalization of $17.45 million, a P/E ratio of -0.74 and a beta of -0.28. Evaxion Biotech A/S has a 52-week low of $2.26 and a 52-week high of $13.61. The firm has a 50-day moving average price of $2.92 and a 200 day moving average price of $3.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invst LLC acquired a new position in Evaxion Biotech A/S during the second quarter worth about $156,000. LM Advisors LLC acquired a new position in Evaxion Biotech A/S during the fourth quarter worth about $231,000. Finally, Armistice Capital LLC grew its position in Evaxion Biotech A/S by 6.8% during the second quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock worth $1,137,000 after buying an additional 25,000 shares during the period. 11.04% of the stock is currently owned by institutional investors and hedge funds.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.